Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jan 30, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 2, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001100682-26-000012
Filed / recorded
Feb 2, 2026, 9:46 PM UTC
Added to OQRO
Oct 2, 2026, 12:27 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Issuer CIK
1100682
Ticker
CRL
Reporting person
James C Foster
Relationship
Director, Officer
Officer title
Chairman, President and CEO
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Jan 30, 2026
Transaction code
A
Shares / units
39,031
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
268,341
Ownership form
Direct
Amendment
No
Footnotes from the filing
Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 26, 2023.
Reflects the exempt transfer pursuant to Rule 16a-13 of (i) 14,577 shares from the 2024 GRAT account to direct holdings; and (ii) 4,048 shares from the 2022 GRAT account to direct holdings.